ARMAVIUS Trademark

Trademark Overview

On Tuesday, July 30, 2019, a trademark application was filed for ARMAVIUS with the United States Patent and Trademark Office. The USPTO has given the ARMAVIUS trademark a serial number of 88549172. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, January 13, 2023. This trademark is owned by Pfizer Inc.. The ARMAVIUS trademark is filed in the Pharmaceutical Products category with the following description:

Pre-filled and pre-assembled bottles and vials sold filled with pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, respiratory, urogenital, urological and viral diseases and disorders, blood disorders, liver disorders, cancer, pain and diabetes; Bottles and vials containing pharmaceuticals for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, respiratory, urogenital, urological and viral diseases and disorders, blood disorders, liver disorders, cancer, pain and diabetes
armavius

General Information

Serial Number88549172
Word MarkARMAVIUS
Filing DateTuesday, July 30, 2019
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, January 13, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 10, 2019

Trademark Statements

Goods and ServicesPre-filled and pre-assembled bottles and vials sold filled with pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, respiratory, urogenital, urological and viral diseases and disorders, blood disorders, liver disorders, cancer, pain and diabetes; Bottles and vials containing pharmaceuticals for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, respiratory, urogenital, urological and viral diseases and disorders, blood disorders, liver disorders, cancer, pain and diabetes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, January 13, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Friday, January 13, 2023ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Friday, January 13, 2023ABANDONMENT - AFTER PUBLICATION
Thursday, January 12, 2023TEAS EXPRESS ABANDONMENT RECEIVED
Saturday, May 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 27, 2022SOU EXTENSION 5 GRANTED
Monday, May 23, 2022SOU EXTENSION 5 FILED
Friday, May 27, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, May 23, 2022SOU TEAS EXTENSION RECEIVED
Thursday, January 6, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 4, 2022SOU EXTENSION 4 GRANTED
Tuesday, January 4, 2022SOU EXTENSION 4 FILED
Tuesday, January 4, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, June 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 14, 2021SOU EXTENSION 3 GRANTED
Monday, June 14, 2021SOU EXTENSION 3 FILED
Monday, June 14, 2021SOU TEAS EXTENSION RECEIVED
Thursday, December 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 8, 2020SOU EXTENSION 2 GRANTED
Tuesday, December 8, 2020SOU EXTENSION 2 FILED
Tuesday, December 8, 2020SOU TEAS EXTENSION RECEIVED
Saturday, June 27, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 25, 2020SOU EXTENSION 1 GRANTED
Thursday, June 25, 2020SOU EXTENSION 1 FILED
Thursday, June 25, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, February 4, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 10, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 10, 2019PUBLISHED FOR OPPOSITION
Wednesday, November 20, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 5, 2019ASSIGNED TO LIE
Tuesday, October 29, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 15, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 14, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 14, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 6, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 6, 2019NON-FINAL ACTION E-MAILED
Friday, September 6, 2019NON-FINAL ACTION WRITTEN
Wednesday, September 4, 2019ASSIGNED TO EXAMINER
Saturday, August 10, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 2, 2019NEW APPLICATION ENTERED

Related Keywords

armavius disorders psychiatric respiratory neuromuscular neurological metabolic musculoskeletal neurodegenerative urogenital viral